John McCamant


Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

Pacira Pharmaceuticals (PCRX) announced positive top line Phase III results for EXPAREL as a single-dose femoral nerve block in the adductor canal for post-surgical regional analgesia in patients undergoing total knee arthroplasty, notes John McCamant, biotech expert and editor The Medical Technology Stock Letter.
BioMarin (BMRN) has received European approval for its gene therapy for Hemophilia A, explains John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
Myovant Sciences (MYOV) delivered strong Q1:22 total revenue of $116.5 million, including net product revenue of $41.4 million, reports John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
Genentech is an excellent, top tier partner for Bicycle Therapeutics (BCYC), a recommendation in our model portfolio, notes JohnMcCamant, editor of Medical Technology Stock Letter— and a participant in The Interactive MoneyShow Virtual Expo, July 26-28. Register here for free.

John's Videos

The Biotech indices have bounced 30% in 30 days (June 16-July 16) as over-sold conditions and biotech/drugs being immune to economic/recession fears have attracted new fund flows.
Among the recently completed Q1 earnings reports, there were a handful of successful biotechs with improving sales/earnings and higher forecasts from new product launches. In biotech, Bear market investors demand positive growth trends from new, approved drugs and avoid regulatory or clinical risk.

Tax loss selling in December offers oversold biotechs that will bounce nicely into the new year, creating what is known as the "January Effect."

Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More